Actinogen Medical LimitedASX: ACW

Actinogen Medical FY21 Results- Progressing the Pipeline

· Issued by Actinogen Medical Limited

Filed with ASX · · 4 pages · English

Key Highlights: • Demonstrated high levels of target occupancy in the brain for Xanamem daily doses ranging from 5mg to 30mg.A relatively flat dose response curve across all doses supports the exploration of doses as low as 5mg in future studies. • Commenced XanaMIA Phase 2 study for Alzheimer’s Disease. The cognition data collected through the successful Phase 1 XanaHES trial in healthy older pat

Actinogen Medical Limited on 6ix

Earlier from Actinogen Medical

Later from Actinogen Medical

All Actinogen Medical news releases